Osaka, Japan – August 15, 2019 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Mitsuo Sawai) received approvals by the Ministry of Health, Labour and Welfare for two generic drugs with five strengths. The two compounds, Aprepitant and Micafungin Sodium are approved for the first time as generics.
The list of approved products:
1. Aprepitant Capsules 80 mg [SAWAI] , 125 mg [SAWAI] and Capsule Set [SAWAI]
|Indications||Digestive symptoms (nausea, vomiting) resulting from the administration of antineoplastic agents (cisplatin, etc.) (including in delayed phase)|
|Brand products||EMEND® Capsules 80 mg, 125 mg and Capsule Set|
2. Micafungin Na 50 mg [SAWAI] for Infusion and 75 mg [SAWAI] for Infusion
|Generic name||Micafungin Sodium|
|Indications||Infections caused by Aspergillus sp. and Candida sp. such as fungemia, respiratory mycosis and gastrointestinal mycosis|
|Brand products||Funguard® 25 mg, 50 mg and 75 mg for Infusion|
The products announced in this press release are not approved by the Food & Drug Administration for sale and distribution in the United States.